Actively Recruiting
Pediatric Germ Cell Tumors: Outcomes, Genomics and Epigenetics
Led by Children's Oncology Group · Updated on 2025-10-24
1151
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are establishing a group of children and adolescents who survived Germ Cell Tumors (GCT) to better understand the short-term and long-term side effects of treatment. They are also studying molecular differences in tumor types to find patterns that might predict outcomes like relapse or death. This observational study focuses on collecting and analyzing clinical and genetic data to improve risk assessment for pediatric GCT survivors. Participants are survivors previously enrolled in related studies who allow access to their medical records, including hearing test results. The study involves collecting tumor and normal tissue samples to analyze DNA changes and methylation patterns. Participants will complete questionnaires about their health and quality of life since treatment, and blood samples will be collected during routine clinic or home visits. During the study, researchers will review medical records and audiograms to assess hearing loss and validate self-reported health outcomes. They will analyze genetic variations and methylation patterns in tumor samples over up to five years. Participants will answer questionnaires and provide blood samples, helping researchers measure treatment effects and molecular markers. The study aims to improve understanding of GCT survivors’ health and guide future care approaches.
CONDITIONS
Brief Title
Molecular Epidemiology of Pediatric Germ Cell Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Primary diagnosis of Germ Cell Tumor including germinoma, teratoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, or mixed GCT in any site including the brain
- Previously enrolled in APEC14B1 with consent to future contact or in AEPI10N1 with consent for future contact
- Diagnosed before 20 years of age at time of Germ Cell Tumor diagnosis
- Able to complete study-related documents in English or Spanish
- Informed consent provided by patients and/or parents or legal guardians; assent for ages 8-17 years
- Compliance with all institutional, FDA, and NCI human study requirements
You will not qualify if you...
- Participants from AEPI10N1 who did not consent to future contact
- Patients unable to complete study materials in English or Spanish
- Patients who do not meet the inclusion criteria described above
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Up to 5 years
Participants who previously had pediatric germ cell tumors are observed through collection of medical records, DNA analysis, and questionnaires about health and quality of life since treatment.
1 or more visits for blood sample collection and questionnaire completion during routine clinic or home visits
Trial Site Locations
Total: 1 location
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
Research Team
J
Jenny Poynter
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here